CD19 and non-small cell lung carcinoma: A trend toward a greater amount of CD19+ B-cells was also identified among NSCLC subjects having CD27(−) cells (75.55; IQR 19.38) compared to healthy individuals with CD27(−) cells (67.50; IQR 18.6; p = 0.0747).